RT Journal Article
SR Electronic
T1 Deep-learning-based white matter lesion volume in CT is associated with outcome after acute ischemic stroke
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.20.23287467
DO 10.1101/2023.03.20.23287467
A1 van Voorst, Henk
A1 Pitkänen, Johanna
A1 van Poppel, Laura
A1 de Vries, Lucas
A1 Mojtahedi, Mahsa
A1 Martou, Laura
A1 Emmer, Bart J.
A1 Roos, Yvo B.W.E.M.
A1 van Oostenbrugge, Robert
A1 Postma, Alida A
A1 Marquering, Henk A.
A1 Majoie, Charles B.L.M.
A1 Curtze, Sami
A1 Melkas, Susanna
A1 Bentley, Paul
A1 Caan, Matthan W.A.
A1 the MR CLEAN No-IV and CONTRAST consortium collaborators
YR 2023
UL http://medrxiv.org/content/early/2023/03/20/2023.03.20.23287467.abstract
AB Background It remains unclear if deep-learning-based white matter lesion (DL-WML) volume can predict outcome after ischemic stroke.Purpose We aimed to develop, validate, and evaluate DL-WML volume in NCCT as a risk factor and IVT effect modifier compared to the Fazekas scale (WML-Faz) in patients also receiving EVT in an EVT-capable center.Methods A deep-learning model for WML segmentation in NCCT was developed and validated internally and externally. The volumetric correspondence of DL-WML volume per mL was reported relative to expert annotation with the intraclass correlation coefficient (ICC) and a Bland-Altman analysis reporting bias and limits of agreement (LoA). In a post-hoc analysis of the MR CLEAN No-IV trial, univariable and multivariable regression models were used to report (un)adjusted common odds ratios ([a]cOR) to associate DL-WML volume and WML-Faz with the occurrence of symptomatic-intracerebral hemorrhage (sICH) and 90-day functional outcome with the modified Rankin Scale (mRS).Results DL-WML volumes were comparable with those of the ground truth for both the internal test set (10/20(50%) male, age median:72[IQR:67-85], ICC mean:0.91 95%CI:[0.87;0.94];bias:-3mL LoA:[-12mL;7mL]) and the external test set (36/101(36%) male, age median:59[IQR:42-73], ICC mean:0.87 95%CI:[0.71;0.95];bias:-2mL LoA:[-11mL;7mL]). 516 patients from the MR CLEAN No-IV trial (291/516(56%) male, age median:71 IQR:[62-79],) were analyzed. Both DL-WML volume and WML-Faz were associated with sICH (DL-WML volume acOR:1.31 95%CI[1.08;1.60], WML-Faz acOR:1.53 95%CI[1.02;2.31]) and mRS (DL-WML volume acOR:0.84 95%CI[0.76;0.94], WML-Faz acOR:0.73 95%CI[0.60;0.88]). Only for the unadjusted analysis, WML-Faz was an IVT effect modifier (p=0.046), DL-WML was not (p=0.274).Conclusion DL-WML volume and WML-Faz had a similar relationship with functional outcome and sICH.Summary statement Deep-learning-based white matter lesion volume in non-contrast CT can substitute human ratings to prognosticate symptomatic intracerebral hemorrhage and functional outcome at 90-days in acute ischemic stroke patients.Key pointsThis was the first study to show that white matter lesion volume in non-contrast CT based on deep-learning segmentations (DL-WML volume) was associated with symptomatic intracerebral hemorrhages and a worse functional outcome.Compared to the Fazekas scale, regression models using DL-WML volume had a similar fit to the data.White matter lesion load might be associated with more symptomatic intracerebral hemorrhages if IVT was given before EVT.Competing Interest StatementDisclosures and conflicts of interest Charles Majoie received funds from, CVON/Dutch Heart Foundation and Stryker, (related to this project, paid to institution) and from European Commission, Healthcare Evaluation Netherlands TWIN Foundation (unrelated to this project; all paid to institution) and is shareholder of Nicolab. Bart Emmer received funds from Health Holland Top Sector Life Sciences, Nicolab, Healthcare Evaluation Netherlands (unrelated to this project; all paid to the institution). Henk Marquering is co-founder and shareholder of Nicolab and TrianecT. Alinda Postma received an institutional grant from Siemens healthineers and Bayer Healthcare. Matthan Caan received funds from Health~Holland Top Sector Life Sciences and Nicolab (unrelated to this project; all paid to the institution) and is shareholder of Nicolab. Paul Bentley is funded by the National Institute for Health Research i4i Program II-LA-0814-20007 and the NIHR Imperial Biomedical Research Centre. The CONTRAST consortium acknowledges the support from the Netherlands Cardiovascular Research Initiative, an initiative of the Dutch Heart Foundation (CVON2015-01: CONTRAST), and from the Brain Foundation Netherlands (HA2015.01.06). The collaboration project is additionally financed by the Ministry of Economic Affairs by means of the PPP Allowance made available by the Top Sector Life Sciences & Health to stimulate public-private partnerships (LSHM17016). This work was funded in part through unrestricted funding by Stryker, Medtronic and Cerenovus. The funding sources were not involved in study design, monitoring, data collection, statistical analyses, interpretation of results, or manuscript writing. Funding StatementFunding: This research was funded by the Dutch Heart Foundation (CVON2015-01)Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:The ethics committee of the Amsterdam UMC waived ethical approval for this work reference: W21_509 # 21.561I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesData will be made available upon reasonable request to the authors. https://www.contrast-consortium.nl/ AISAcute ischemic strokeNCCTnon-contrast CTDL-WML volumedeep-learning-based white matter lesion volumeWML-FazWhite matter lesion load according to the Fazekas ScaleIVTintravenous thrombolysisEVTendovascular treatmentsICH/aICH(a)symptomatic intracerebral hemorrhagemRSmodified Rankin ScaleDSCDice similarity coefficientHDHausdorff distance in mm